
Amarin Corporation plc AMRN
$ 13.66
0.44%
Quarterly report 2025-Q2
added 07-30-2025
Amarin Corporation plc Cash Conversion Cycle 2011-2025 | AMRN
Annual Cash Conversion Cycle Amarin Corporation plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157 | 146 | 99.6 | 80.5 | 201 | 241 | 133 | 210 | 168 | 146 | 504 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 504 | 80.5 | 190 |
Quarterly Cash Conversion Cycle Amarin Corporation plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 249 | - | 255 | 162 | 201 | - | 169 | 146 | 140 | - | 62.6 | 53.3 | 741 | - | 662 | 479 | 452 | - | 319 | 367 | 224 | 74.2 | 191 | 213 | 239 | 78.5 | 246 | 259 | 224 | 76.8 | 126 | 132 | 86 | 47.1 | 55.7 | 55.1 | 60.4 | 47.4 | 58.7 | 71.2 | 62 | 43.4 | 50.6 | 56.8 | 47.8 | 32.9 | 39.6 | 60.5 | 71 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 741 | 32.9 | 170 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.68 | -0.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
-881 | $ 2.9 | -5.54 % | $ 224 M | ||
|
Aptevo Therapeutics
APVO
|
-47.4 | $ 1.02 | -7.27 % | $ 282 K | ||
|
Catalyst Biosciences
CBIO
|
391 | $ 12.12 | -2.65 % | $ 798 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
Celldex Therapeutics
CLDX
|
-6.08 K | $ 26.58 | -2.53 % | $ 1.71 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
-186 | $ 81.99 | -3.67 % | $ 8.46 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
54.2 | $ 24.23 | -0.33 % | $ 2.87 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Dynavax Technologies Corporation
DVAX
|
459 | $ 11.13 | -0.27 % | $ 1.45 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 26.45 | -3.18 % | $ 1.28 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 9.39 | -0.32 % | $ 138 M | ||
|
Eton Pharmaceuticals
ETON
|
-6.66 | $ 16.55 | -0.12 % | $ 424 M | ||
|
Evogene Ltd.
EVGN
|
-32.5 | $ 1.05 | 1.46 % | $ 27.9 M | ||
|
Exelixis
EXEL
|
5.31 | $ 46.61 | 0.91 % | $ 13.5 B | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Axon Enterprise
AXON
|
86.2 | $ 591.02 | -1.53 % | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.54 | -4.15 % | $ 16 M | ||
|
AstraZeneca PLC
AZN
|
-58 | $ 92.14 | 0.64 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 10.5 | -4.55 % | $ 679 M | ||
|
Biogen
BIIB
|
387 | $ 174.82 | 0.07 % | $ 25.5 B |